Exercise Mimetics Ranked: Which Ones Actually Work?
Ca-AKG, urolithin A and MOTS-c tie at 6.5, and only the first two are things you can legally buy. SS-31 follows at 6.0. The bottom three score low…
- Urolithin A
- Ca-AKG
- MOTS-c
- SS-31
- +3 more
Every intervention Outliyr has scored for muscle growth, ranked by its BioHarmony score for this use case rather than its overall rating. The number beside each name is how well that one thing works for muscle growth; the tier beside it is what it is worth once safety, cost and effort are counted across everything else.
34 of 84 evaluated interventions score 3.0+ out of 10 for muscle growth · 18 comparisons
Essential Amino Acids is a 8.5/10 muscle growth fit because Jackman 2017 reports Corrected PMID from audit; supports acute BCAA anabolic direction, not stand-alone long-term EAA outcome claims. Kirwan 2022 points in…
Read the Essential Amino Acids report →For muscle growth, Creatine Monohydrate scores 8.0/10 because Chilibeck 2017 reports Older adults; +1.37 kg lean mass; leg press SMD 0.24. Delpino 2022 points in the same direction, but route, dose, baseline…
Read the Creatine Monohydrate report →Grass-Fed Whey Protein scores 7.5/10 for muscle growth because whey protein directly supplies leucine-rich amino acids needed for muscle protein synthesis. The strongest support comes from Shimomura Y. et al. 2006, but…
Read the Grass-Fed Whey Protein report →Blood-Flow Restriction Training scores 7.5/10 for muscle growth, with the best signal coming from Patterson et al. 2019. Meta-analyses including Lixandrao 2018 confirm low-load BFR can produce hypertrophy similar to heavy-load training…
Read the Blood-Flow Restriction Training report →The strongest muscle growth argument for TRT (Testosterone Replacement Therapy) is 7.5/10 because Bhasin 1996 reports Classic androgen dose-response trial; supports anabolic mechanism but used supraphysiologic dosing in normal men, not standard…
Read the TRT (Testosterone Replacement Therapy) report →For readers prioritizing muscle growth, Full-Body EMS scores 6.0/10 today. WB-EMS recruits high-threshold motor units through involuntary contraction. Kemmler 2021 and Rodrigues-Santana 2023 support muscle-mass gains, but effect size depends heavily on…
Read the Full-Body EMS report →Glycine muscle growth earns 5.5/10 because Soh 2024 anchors the most relevant signal. Glycine fits muscle growth because glycine participates in sleep signaling, glutathione, collagen, methylation, and nervous-system balance, depending on the…
Read the Glycine report →The evidence for Whole-Body Vibration in the muscle-growth use case rates a 5.5/10 score, based on the modest torque gains reported in Peng et al. 2024. Whole-Body Vibration alone produces only small…
Read the Whole-Body Vibration report →The practical muscle-growth read on Tongkat Ali is 5.5/10 because Leisegang 2022 anchors the strongest signal. The existing rationale points to this narrower claim: the cited study is the main lean-mass citation,…
Read the Tongkat Ali report →CJC-1295 is a 5.5/10 muscle growth fit because Teichman 2006 reports CJC-1295 human pharmacology; supports sustained GH/IGF-1 increase and short-duration tolerability, not body-composition or longevity outcomes. Ionescu 2006 points in the same…
Read the CJC-1295 report →A 5.2/10 for muscle-growth fits Ca-AKG (Calcium Alpha-Ketoglutarate) because Shahmirzadi 2020 supports direction more than certainty. The existing rationale points to this narrower claim: No hypertrophy RCT data. Nitrogen-balance and burn-care literature…
Read the Ca-AKG (Calcium Alpha-Ketoglutarate) report →Population fit explains the 5.0/10 muscle growth score for Ashwagandha because the evidence points to a plausible use case without proving a universal response. Ferreira et al. 2025 is the best anchor…
Read the Ashwagandha report →For muscle growth, Urolithin A lands at 5.0/10 because context matters. Human data support a modest muscle-performance signal more than hypertrophy. ATLAS and older-adult trials suggest strength/endurance effects, but not clear muscle-mass…
Read the Urolithin A report →Accelerates muscle fiber repair; indirect support for training recovery. BPC-157 is not a proven hypertrophy agent, and WADA status should keep tested athletes away from performance-framed use.
Read the BPC-157 report →Testosterone, collagen-marker, and strength-retention findings support a modest muscle-growth adjacency, but hypertrophy outcomes have not been directly tested.
Read the Shilajit report →GH/IGF-1 signaling can support lean tissue, and Adrian 2019 found increased trunk muscle area and density in HIV tesamorelin responders. Strength transfer and direct hypertrophy outcomes remain modest.
Read the Tesamorelin report →Reduced muscle damage could support training frequency, but no direct hypertrophy evidence supports a higher score.
Read the Astaxanthin report →Muscle growth is supported by the lean-mass data but undercut by what that mass did, which is why it lands mid-range. The Nass 2008 trial confirmed about 1.1 kg of fat-free mass…
Read the MK-677 (Ibutamoren) report →Minimal hypertrophy signal. Cycling or uphill running can preserve some lower-body capacity, but the stimulus is cardiovascular rather than mechanical-tension dominant.
Read the Norwegian 4×4 report →Sprints recruit and preserve fast-twitch muscle but are not a primary hypertrophy stimulus. Keep resistance training if muscle growth is the goal.
Read the Sprinting (Sprint Interval Training) report →mTOR inhibition works against muscle protein synthesis signaling; users commonly avoid dose day near hard resistance training.
Read the Rapamycin report →Improved mitochondrial function supports muscle bioenergetics, but no direct hypertrophy trial exists; the FDA approval is muscle strength in Barth syndrome, not muscle growth.
Read the SS-31 (Elamipretide) report →Aged mice nearly doubled muscle-fiber size after injury (Neelakantan 2019), yet this is an aging-rescue pathway with no evidence it transfers to young, healthy users.
Read the 5-Amino-1MQ report →The mechanism favors oxidative remodeling rather than hypertrophy. Billon et al. 2023 reported oxidative fiber changes, but no muscle-growth, lean-mass, or resistance-training endpoint exists in humans.
Read the SLU-PP-332 report →Cell hydration supports normal training and protein-synthesis context, but electrolyte blends are permissive rather than anabolic.
Read the Electrolytes report →Muscle-growth stays low because GHK-Cu is not a direct anabolic. Collagen and connective-tissue support may help recovery context, but hypertrophy evidence is absent. Pickart 2018 supports tissue-remodeling biology, not muscle gain.
Read the GHK-Cu report →Walton 2019 is a direct negative for hypertrophy-focused users. Metformin is a poor fit for older adults prioritizing resistance-training adaptation unless a clinician has a stronger metabolic reason.
Read the Metformin report →Bovine colostrum contains growth factors, but oral growth factors do not reliably create systemic anabolic signaling. Muscle-growth evidence is weaker than creatine, protein sufficiency, and progressive overload.
Read the Colostrum report →Hypertrophy benefit is not reliable. Early muscle-protein-synthesis enthusiasm has not translated into consistent strength or lean-mass gains across newer controlled work.
Read the Omega-3 report →Omi 2019 EMIQ plus protein in 40 male athletes showed body composition gains that may include lean mass context. Direct hypertrophy RCTs in resistance-trained adults are not available for quercetin alone. mTOR…
Read the Quercetin report →MOTS-c is not primarily anabolic. AMPK activation can compete with mTOR-driven hypertrophy signaling, so muscle-growth claims should stay modest despite Reynolds 2021 muscle-homeostasis data.
Read the MOTS-c report →No direct hypertrophy evidence supports NMN. Muscle-function data are older-adult and endurance-adjacent, not muscle-growth evidence.
Read the NMN (Nicotinamide Mononucleotide) report →Muscle gain is harder during appetite suppression and weight loss; the protocol must include progressive training and high protein.
Read the Semaglutide report →No human muscle-growth trial exists for GHRP-6. The growth-hormone pulse it produces is real but far smaller than exogenous growth hormone, per Jaffe 1993, and nothing has been measured for hypertrophy in…
Read the GHRP-6 report →Nothing matches those filters.
Head-to-head reports and category rankings that name a winner on this use case.
Ca-AKG, urolithin A and MOTS-c tie at 6.5, and only the first two are things you can legally buy. SS-31 follows at 6.0. The bottom three score low…
Tesamorelin, at 6.2, and only if you have a clinical reason. Every one of the nine scores 6.2 or lower, so the category tops out at worth trying…
Shilajit at 7.4, phosphatidylserine at 7.3, tongkat ali at 7.0. TRT ranks seventh at 5.7 and wins nine of the eleven use cases outright. That inversion is the…
Neither, if fat loss is the goal. Both score 2.0 on body composition, which is the row a vendor sells them on. AOD-9604 scores 4.6 overall and its…
No. Berberine scores 6.8 and semaglutide 6.0, and that gap misleads almost everyone who reads it. Berberine scores higher because it is cheap, oral and easy to stop,…
Tesamorelin, unless price is the only thing deciding. It is FDA-approved for visceral fat with Phase 3 trials behind it, while CJC-1295 is a gray-market research peptide whose…
These two get sold as the same thing, a scoop for gut and skin, and they share almost no mechanism. Colostrum is a gut and immune product: gut…
The scores tie at 6.3 and 6.4 and every shared subrating sits within half a point, so the numbers decide nothing. Access and evidence decide it. Gonadorelin is…
Kisspeptin-10 scores 6.4 and TRT 5.7, and TRT still wins 13 of the 15 use cases both reports score. The higher number reflects dependency and reversibility, not effect.…
Start on sermorelin. Ipamorelin scores higher overall, yet sermorelin wins thirteen of the sixteen shared use cases and it is the one an anti-aging clinic actually prescribes. Ipamorelin…
Shilajit scores 7.4 and ashwagandha 6.8, but that gap is the least useful number here. These two do different jobs. Shilajit is the mineral and androgen play: male…
Spermidine scores 7.6 and urolithin A 6.5, and they clean up different messes. Spermidine drives broad autophagy: autophagy 8.0, cardiovascular 7.8, longevity 7.5. Urolithin A drives selective mitophagy…
Essential Amino Acids, at 8.5 out of 10 for muscle growth. Essential Amino Acids is a 8.5/10 muscle growth fit because Jackman 2017 reports Corrected PMID from audit; supports acute BCAA anabolic direction, not stand-alone long-term EAA outcome claims.
Of the top-scoring options, Glycine is the least expensive at about $2 a month, scoring 5.5 out of 10 for muscle growth.
34 of the 84 interventions evaluated for muscle growth score 3.0 out of 10 or better, which is the cut-off for appearing on this page.